EGFR and neoplasm: Even though EGFR antibodies showed no benefit to treat PDAC patients, a study by Blasco and collaborators showed that genetic removal of EGFR and CRAF kinase in a mouse model induced the regression of PDAC tumours in vivo, suggesting that a combination of EGFR and CRAF inhibitors could be of interest for PDAC treatment [25], but this has still to be assessed.